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Abstract
Human pluripotent stem cells (hPSCs) offer a multifaceted platform to study cardiac developmental biology, understand 
disease mechanisms, and develop novel therapies. Remarkable progress over the last two decades has led to methods to 
obtain highly pure hPSC-derived cardiomyocytes (hPSC-CMs) with reasonable ease and scalability. Nevertheless, a major 
bottleneck for the translational application of hPSC-CMs is their immature phenotype, resembling that of early fetal cardio-
myocytes. Overall, bona fide maturation of hPSC-CMs represents one of the most significant goals facing the field today. 
Developmental biology studies have been pivotal in understanding the mechanisms to differentiate hPSC-CMs. Similarly, 
evaluation of developmental cues such as electrical and mechanical activities or neurohormonal and metabolic stimulations 
revealed the importance of these pathways in cardiomyocyte physiological maturation. Those signals cooperate and dictate 
the size and the performance of the developing heart. Likewise, this orchestra of stimuli is important in promoting hPSC-
CM maturation, as demonstrated by current in vitro maturation approaches. Different shades of adult-like phenotype are 
achieved by prolonging the time in culture, electromechanical stimulation, patterned substrates, microRNA manipulation, 
neurohormonal or metabolic stimulation, and generation of human-engineered heart tissue (hEHT). However, mirroring this 
extremely dynamic environment is challenging, and reproducibility and scalability of these approaches represent the major 
obstacles for an efficient production of mature hPSC-CMs. For this reason, understanding the pattern behind the mechanisms 
elicited during the late gestational and early postnatal stages not only will provide new insights into postnatal development 
but also potentially offer new scalable and efficient approaches to mature hPSC-CMs.
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Introduction
The discovery of human pluripotent stem cells (hPSCs) 
has revolutionized cardiovascular biology [1–3]. Over 
the last two decades, methods to differentiate cardiomyo-
cytes from human pluripotent stem cells (hPSCs, either 
embryonic stem cells—hESCs, or -induced pluripotent 
stem cells—hiPSCs) have been refined and streamlined 
[4–7]. State-of-the-art protocols allow the production of 
highly pure cells with the main features of either work-
ing (i.e., ventricular and atrial) or pacemaker myocytes 
[8–10]. Such bona fide hPSC-derived cardiomyocytes 
(hPSC-CMs) contract spontaneously and show action 
potentials and calcium transients similar to their in vivo 
counterparts. Accordingly, they express the main cardiac 
ion channels and sarcomeric proteins involved in excita-
tion–contraction coupling. This provides a cost-effective 
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and renewable source of cardiomyocytes for a plethora 
of applications such as developmental biology [11, 12], 
pharmacology [13, 14], disease modeling [15, 16], and 
regenerative medicine [17–19]. For instance, hPSC-CMs 
are becoming a prominent model to evaluate the potential 
cardiac toxicity of novel drugs, which represents one of 
the most significant bottlenecks in the drug development 
pipeline [14, 20, 21]. Moreover, hPSC-CMs are emerging 
as a promising therapeutic approach for cardiac regenera-
tion [22, 23], as their transplantation into infarcted hearts 
of nonhuman primates leads to efficient remusculariza-
tion and electrical coupling, which can prevent adverse 
remodeling of the myocardium and restore its mechanical 
function [19, 22, 24].
Despite these exciting applications, a major obstacle that 
prevents harnessing the full potential of hPSC-CMs is repre-
sented by their immature phenotype. Among other features, 
hPSC-CMs are a fraction of the size of adult cells, are much 
weaker, exhibit persistent automaticity and lack their typical 
rod-shaped morphology. Moreover, hPSC-CMs are metabol-
ically dependent on glucose rather than fatty acid oxidation 
and lack key structural features such as transverse tubules 
(T-tubules) [25, 26]. Indeed, from an epigenetic and tran-
scriptional point of view, hPSC-CMs most closely resem-
ble fetal cardiomyocytes [11, 27, 28]. Improving hPSC-CMs 
maturation is thereby one of the most ambitious challenges 
faced by the field today.
Lessons from embryonic development have been pivotal 
in informing the establishment of methods for the differen-
tiation and maturation of hPSC-CMs [3, 7, 29]. For instance, 
the study of WNT signaling during early embryogenesis [7, 
30] paved the way to methods which rely on biphasic modu-
lation of the WNT pathway to first induce mesoderm (WNT 
activation) and then specify cardiac progenitors (WNT 
inhibition [7]). Similarly, the evaluation of hormone levels 
throughout fetal and postnatal development [31, 32] unveiled 
the role of triiodothyronine (T3) and glucocorticoids in pro-
moting multiple aspects of hPSC-CM maturation [33, 34]. 
In a similar vein, we submit that the development of scalable 
and efficient strategies for hPSC-CM maturation will require 
careful examination of cardiac development during both the 
late gestational and postnatal periods. However, an updated 
and comprehensive collection of the available information 
appears, to the best of our knowledge, to be lacking.
This review addresses this limitation by summarizing our 
current understanding of the fundamental mechanisms in 
late gestation and postnatal life that drive the physiological 
maturation of embryonic cardiomyocytes toward an adult 
phenotype. We discuss how some of these paradigms have 
already been implemented to promote hPSC-CM maturation, 
and we highlight benefits and limitations of current tech-
nologies. We conclude by assessing the missing pieces in 
the cardiac maturation puzzle and by suggesting future areas 
of research both in vivo and in vitro. Due to its relevance 
to most current applications of hPSC-CM technology, this 
review is centered on the ventricular cardiomyocyte subtype.
Gestational Cardiac Development
Acquisition of the cardiac cell fate is tightly interwoven 
with the morphogenetic events that underpin the formation 
of the heart in utero. Throughout this process, a number of 
changing factors in the extracellular milieu contribute to 
the first key stages of cardiomyocyte maturation. Unfortu-
nately, gestational maturation has been much less studied 
than the earlier processes of cell type specification and 
organ morphogenesis. Furthermore, animal models will 
not perfectly predict human cardiomyocyte maturation [35, 
36], and the scarcity of human samples at this develop-
mental stage limits our understanding human-specific ele-
ments of maturation. Here we summarize what we know 
about this “black box” of cardiac development.
Morphogenetic Events
The human heart is the first organ to form during embryo-
genesis. This is a complex, multistep process requiring 
fine orchestration of different cell populations [37, 38]. 
During gastrulation, the pluripotent epiblast gives rise to 
a multilayered structure composed by endoderm, meso-
derm, and neuroectoderm [38]. A subset of cells local-
ized in the lateral plate mesoderm gives rise to two main 
cardiogenic populations named first and second heart field 
(FHF and SHF). These are organized in a bilaterally sym-
metric structure detectable at human embryonic develop-
ment day 18 (E18; E7.5 in mice) [37, 39]. Cells from the 
FHF migrate and fuse at the midline, generating the primi-
tive heart tube by E20 (E8 in mice) [39]. This structure 
is composed by an outer layer of myocardial cells, which 
predominantly contribute to the working myocardium of 
the left ventricle, and an inner layer of endocardial cells, 
which develop into the heart valves and the deep coronary 
circulation [40]. These layers are separated by an acellular 
hydrophilic matrix named cardiac jelly [40]. This structure 
contains paracrine signals that drive the epithelial–mesen-
chymal transition (EMT) of endocardial cells into mesen-
chymal cells, which then proliferate and invade the cardiac 
jelly [41]. This process generates the endocardial cushion, 
which lines the atrioventricular canal and the outflow tract, 
and is the precursor of heart valves [42]. The slowly dif-
ferentiating cells from the SHF integrate into the form-
ing heart at the arterial and venous poles, and contribute 
to the right ventricle, to parts of the left and right atria, 
and to the outflow tract [43, 44]. Another population of 
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mesodermal cells in the so-called pro-epicardium, local-
ized dorsally to the heart tube, gives rise to epicardial cells 
[45]. In addition to forming the mesothelial cells that line 
the heart’s outer surface, epicardial cells are precursors of 
multiple cell lineages that contribute to the generation of 
the interstitium and the vasculature such as cardiac fibro-
blasts and coronary vascular smooth muscle cells [46, 47].
The heart’s pacemaking centers, the sinoatrial node 
(SAN), and atrioventricular node (AVN), are another cru-
cial component for the developing heart. Lineage tracing 
experiments in mouse and chick embryos demonstrated that 
pacemaker cells arise from a defined lateral plate mesoderm 
population separated from the FHF and the SHF, suggesting 
that it constitutes a “tertiary heart field” [48–50]. Cells of 
the SAN seems to be segregated early in the sinus veno-
sus region of the heart tube under the regulation of T-box 
(Tbx) transcription factors Tbx18/Shox2/Tbx3 [51]. This 
cell population has the fastest beating rate and therefore 
dictates the pace of the entire heart [51]. At this stage, the 
ECG recording shows a sinusoidal wave, starting from the 
caudal region and slowly diffusing throughout the heart 
tube, resulting in peristaltic contraction [52, 53]. The AVN 
forms later than the SAN and rises from the crest of the 
interventricular septum under the control of Tbx3. This tran-
scription factor, together with Tbx18 and Shox2, represses 
working myocardial genes (Gja5/Cx40, Gja1/Cx43, Nppa/
ANF, Scn5a/Nav1.5) and promotes expression of Cx30.2 
and Hcn channels [51]. The presence of the low-conductance 
Cx30.2 in these regions delays the propagation of the electri-
cal impulse; indeed, in the mammalian heart, the electrical 
conductance of Cx30.2 is 9 pS compared to 162 pS of Cx40, 
expressed in the ventricular conduction system [54]. The 
different expression of gap junctions is crucial for estab-
lishing the unidirectional propulsion of the blood flow in 
the absence of the valves [55]. The His-Purkinje conduction 
system is derived from a population of working ventricular 
myocytes expressing Cx40, but negative for Tbx3, and is 
responsible for rapid propagation of the electrical impulse 
distal to the AVN [56, 57]. This population remains segre-
gated within the trabecular myocytes during development, 
as demonstrated in lineage tracing experiments by labeling 
Gja5/Cx40-expressing cells [56].
Finally, cardiac neural crest cells migrating from the 
neural tube contribute to cardiac septation by mediating the 
symmetrical development of the endocardial cushion and 
the septation of the outflow tract into the pulmonary artery 
and aorta [58].
During early- and mid-gestational periods, the heart 
undergoes a number of complex morphological changes. 
The heart tube can be divided into the truncus arteriosus, 
bulbus cordis, ventricle, and sinus venosus, as shown in 
Fig. 1. Starting from E23 and until E35 (E8.5–E10.5 in 
mice), the straight heart tube gradually transforms into a 
helically wound structure in a process called cardiac looping 
[59]. This begins with the movement of the upper portion 
(truncus arteriosus and bulbus cordis) in a ventral and cau-
dal direction, creating a C-loop shape pointing toward the 
right side of the embryo (Fig. 1, E24). In the consecutive 
S-looping phase, the ventricle moves dorsally and crani-
ally, pulling along the atria. During this phase, the distance 
between the arterial pole and the venous pole shortens, 
and the ventricular portion shifts below the atrial segment 
[59]. This process establishes the left–right asymmetry of 
the future ventricle chambers (and indeed, the first lateral 
asymmetry in the embryo) and imparts the definitive topo-
logical relationship between the different parts of the heart, 
including the great vessels [59]. After cardiac looping, car-
diomyocytes and endocardial cells in the ventricular wall 
proliferate and form sponge-like structures called trabecular 
ridges. Trabeculation both facilitates nutrient exchange and 
enhances contractile force generation in order to respond to 
the increasing blood and oxygen demands of the developing 
embryo, due to the lack of coronary vasculatures [60, 61]. 
The trabecular ridges are constituted by clusters of cardio-
myocytes loosely attached to the compact myocardium and 
surrounded by endocardial cells [60, 62]. As development 
proceeds, cardiomyocytes adjacent to the epicardium are 
characterized by increased proliferation rate, whereas the 
cardiomyocytes closer to the endocardium are more differ-
entiated [60, 62].
Heart partitioning in the four chambers is due to the for-
mation of the interventricular septum, the interatrial septum, 
and the atrioventricular valves [63]. Between E35 and E40, 
the endocardial cushions move toward each other until they 
fuse to form the primitive interventricular septum, subdivid-
ing the right and left atrioventricular canals. The mesen-
chyme around each canal proliferates and forms the atrioven-
tricular valves [42]. The two atria are subsequently separated 
by the septum primum and septum secundum, while the 
blood can flow from the right to the left atria through the 
foramen ovale, bypassing the pulmonary circulation (Fig. 1). 
Septation is completed by day E55 (E15.5 in mice), at which 
point the heart becomes a four-chambered, fully functional 
organ. During this time, epicardial cells undergo extensive 
proliferation and migration, to eventually cover the entire 
embryonic heart by E34 (E11.5 in mice) [45]. From ges-
tational week 8 (E18.5 in mice) and throughout the post-
natal period, most of the trabeculae collapse toward the 
myocardial wall forming a thicker, compact structure [61, 
64]. Finally, the myocardial wall further matures in a mul-




Environmental Dynamics of the Gestational Heart
The morphological changes happening during heart devel-
opment are governed both by mechanical forces exerted on 
the myocardial wall by the blood flow and the availability 
of energy substrates like oxygen and carbon sources which 
ultimately affect cardiogenesis on both a cellular and a 
molecular level.
During the early stage of embryogenesis, the first heart 
beat in humans can be observed as soon as day E22 (E8 
in mice), and this seems to drive the development of pri-
mordial hemodynamic forces that eventually will promote 
cardiac development [67]. In the straight heart tube phase, 
the blood flow is barely detectable but becomes substantial 
after cardiac looping, due to the formation of the cham-
bers and the development of coronary vasculature [68]. 
This results in an increased blood pressure and mechani-
cal strain to which fetal cardiomyocytes are exposed. The 
blood pressure measured in human fetuses showed a lin-
ear increase with advancing gestation, with the left and the 
right ventricular systolic pressures ranging between 28 and 
45 mmHg from the 20th and 40th gestational weeks [67, 69]. 
Evaluation of mechanical strain across the myocardial wall 
also revealed an increasing strain gradient from the compact 
myocardium toward the inner layer of the heart [70]. These 
differences affect the phenotype of the fetal cardiomyocytes. 
Cells become elongated and have decreased mitotic activ-
ity in the region exposed to increased mechanical forces, 
like trabecular cardiomyocytes [60, 62, 70]. The formation 
of the different septa and valves, and the development of 
the coronary vasculature also modifies the hemodynamic 
flow within the heart, where laminar blood flow dominates 
the early fetal stage and turbulent flow becomes predomi-
nant during chamber formation. Indeed, wall shear stress 
increases from 80 to 250 dynes/cm2 as evaluated in chick 
embryos between HH23–27 [67].
The role of hemodynamic forces in cardiac development 
has been demonstrated in a variety of animal models in 
which blood flow was impaired by either occlusion of the 
outflow tract [71] or ligation of the left atrium [72]. In these 
models, manipulation of blood flow resulted in impaired car-
diac morphogenesis, with hypoplasia of the left ventricular 
wall and trabeculae noncompaction [67, 71, 72].
Fig. 1  Human embryonic heart development. The primitive heart 
tube forms by human embryonic day 22 (E22) and is divided in four 
different regions: from head to tail, the truncus arteriosus will give 
rise to the aorta and the pulmonary trunk; the bulbus cordis will 
develop into the right ventricle; the ventricle region will form the 
left ventricle and the anterior portion of the right and the left atria; 
and the sinus venosus develops into the posterior portion of the right 
atrium, the SA node, and the coronary sinus. By E24, the heart tube 
starts to bend in a primitive C-shape. Ventricular myocytes undergo 
trabeculation, whereas the endocardial cells start to migrate into the 
endocardial cushions. By E28, the heart tube creates a S-shape with 
the primordial division of the four chambers. By E56, the fetal heart 
is completely formed; the septa primum and secundum divide the two 
atria, which remain connected through the foramen ovale, while the 
endocardial cells from the cushions give rise to the tricuspid and the 




Although the precise molecular mechanism by which 
hemodynamic forces affect cardiomyocytes maturation is 
still not fully determined, endocardial–myocardial commu-
nication seems to control the architecture of the developing 
heart by expression of different signals, including Notch 
and neuregulin-1 (NRG1) [61, 73]. Indeed, apical expres-
sion of NRG1 promotes trabeculae expansion by increasing 
extracellular matrix (ECM) synthesis [61, 74]. Vice versa, 
the expression of the Notch signaling components delta-like 
canonical Notch ligand-4 and Notch1 intracellular domain 
(DLL4-N1ICD) at the base of the nascent trabeculae pro-
motes cardiomyocytes proliferation by activating bone mor-
phogenic protein 10 (BMP10) [75] and thus, suppressing the 
cell-cycle inhibitor  p57kip2 [75, 76].
The high proliferative rate of early fetal cardiomyocytes 
is also associated with their predominant metabolic substrate 
for energy production: glucose. Glycolysis is the catabolic 
pathway that most efficiently provides the main biosynthetic 
precursors for macromolecules such as nucleic acids, lipids 
and proteins, all of which are required at high levels in rap-
idly proliferating cells [77]. Accordingly, the ventricular 
wall of fetuses from diabetic mothers show hyperplasia and 
increased thickening, a feature that is often resolved within 
months after birth as the exposure to the hyperglycemic 
intrauterine milieu ends [78]. In the fetus, the abundance of 
glucose and lactate combined with the paucity of fatty acids 
(less than 0.1 mM) and the low oxygen levels favor anaero-
bic glycolysis over fatty acid β-oxidation [79, 80]. Indeed, 
plasma lactate levels in the fetus are ~ 5 mM, compared to 
approximately 0.5 mM in the adult [81]. Such high levels of 
lactate repress fatty acid β-oxidation via the so-called Randle 
Cycle, also known as the glucose/fatty acid cycle [79]. As a 
result, more than 80% of ATP produced by fetal cardiomyo-
cytes comes from glycolysis [79]. The anaerobic metabolism 
of fetal cardiomyocytes is also favored by the expression 
of specific glycolytic enzymes [82]. In the late stages of 
pregnancy, the expression of transcripts related to fatty acid 
oxidation markedly increases [82]. Thus, during this late 
fetal stage the metabolism starts to switch to become less 
dependent on glucose and more favorable for fatty acid oxi-
dation. The mechanism that regulates this metabolic switch 
is still largely unknown, but repression of HIF1 signaling 
represents a valid candidate for future investigation, due to 
its role in the regulation of both energy metabolism and cell 
proliferation [83–85]. Interestingly, there is a gradient of 
VHL/HIF1 expression from the compact myocardium (high 
expression) toward the trabecular myocytes (low expression) 
[85]. This could correlate with the increased proliferation, 
decreased differentiation, and reduced mitochondrial oxida-
tive activity observed in the compact myocardium.
Postnatal Cardiac Development
Environment of the Postnatal Heart
The transition from the intrauterine to extrauterine life is 
arguably the most complex adaptation that occurs in human 
experience. At birth, the loss of the placenta deprives the 
fetus of an important source of energy substrates and hor-
mones. The removal of the umbilical cord and the recruit-
ment of the lungs, together with the exposure of the newborn 
to a relatively cold environment trigger both physical and 
endocrine signals in order to ensure the survival in the post-
natal life [31, 32, 80, 86].
Cortisol represents one of the major regulatory hormones 
responsible for neonatal adaptation [32]. Indeed, during fetal 
life in human, plasma cortisol is very low but it gradually 
starts to increase around late gestational period (it ranges 
from 2 to 50 µg/dL in preterm infants [87]) and reaches a 
peak at labor, with levels four times higher compared to that 
of gestational stage [86]. This results in the maturation of the 
lungs associated with the clearance of fetal fluid, activation 
of thermogenesis as well as metabolic adaptation. Moreover, 
the expression of mitochondrial membrane protein UCP1 
(uncoupling protein1) increases and, together with the boost 
in catecholamine secretion, thermogenesis is initiated in the 
brown adipose tissue [88]. Cardiomyocyte maturation is 
also promoted by glucocorticoids as demonstrated in vivo 
by administration of betamethasone to preterm piglets [89]. 
Indeed, treatment with glucocorticoids 24 and 48 h before 
delivery increases the number of binucleated cardiomyo-
cytes in piglets, characterized also by reduced proliferation 
capability [89]. At the molecular levels, cortisol influences 
these processes potentially by increasing the expression of 
peroxisome proliferator-activated receptor PPAR-γ coacti-
vator (PGC1α) [90]. PGC1α indeed acts as a coactivator 
for a variety of transcription factors involved in different 
biological responses such as thermogenesis, mitochondria 
biogenesis and metabolic control [91].
Thyroid hormones (TH) signaling in the fetus starts to 
be detectable only at 35–40 weeks of gestation. During 
fetal life, the thyroid receptor system is completely devel-
oped by the 12th gestational week, however the serum 
concentration of T3 and T4 are very low until the hypo-
thalamus–pituitary–thyroid gland axis becomes fully func-
tional [31]. Maternal thyroid hormones have limited ability 
to cross the placental barrier, indeed placental expression 
of type 3 iodothyronine monodeiodinase deactivates both 
T4 and T3 to their inactive counterparts [31, 92]. At birth, 
the amount of thyroid hormones dramatically increases to 
peak at high levels of about 300 ng/dL for T3 [31], 12 µg/
dL for T4 as well as an eightfold increase of TSH levels 
[92]. This increase could be triggered by both the surge in 
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cortisol [86] and the acquisition of homeothermy with the 
initiation of thermogenesis [31, 92]. The effects of thyroid 
hormones are mainly due to the activation of thyroid hor-
mone receptors (THRα and THRβ), expressed in the nucleus 
of the cells but also could be exerted by the αvβ3-mediated 
integrin signaling [31, 93], although this pathway is still not 
investigated in cardiomyocytes [94]. TH modulates cardio-
myocytes inotropic maturation by modulating the expression 
of calcium handling and sarcomere proteins, and induces a 
hypertrophic response by increasing cell size [31, 94, 95]. 
The spike in TH at birth is also associated with cardiomyo-
cytes cell-cycle withdrawal [31]. Indeed, cardiomyocytes 
with impaired TH signaling showed increased proliferation 
and decreased polyploidization [96]. Moreover, TH seems 
to control the expression of Glut1 and Glut4 during rat heart 
development. These two glucose transporters are differen-
tially regulated during development, with GLUT1 highly 
expressed in the fetal stage, whereas GLUT4 becomes the 
main glucose transporter in the adult stage [80, 97]. Translo-
cation of GLUT4 to the cytoplasmic membrane is regulated 
by insulin, whereas GLUT1 constitutively localizes to the 
plasma membrane once it is synthesized, independent of 
insulin. Administration of T3 to hypothyroid rats showed 
increased expression of Glut4 combined with decreased lev-
els of Glut1; thus, indicating a TH involvement in postnatal 
metabolic adaptation [97].
Circulating catecholamines, i.e., noradrenaline, adrena-
line and dopamine increase up to tenfold at birth, due to both 
the maturation of adrenal medulla and the loss of placental 
clearance of catecholamines [86]. Cardiomyocytes’ respon-
siveness to adrenergic stimuli is already present in fetal car-
diomyocytes, although β-adrenergic stimulation results only 
in increased chronotropism without inotropic effects, poten-
tially due to the low number of receptors and the absence 
of phospholamban, an adrenergic-responsive regulator of 
SERCA2a activity [98, 99]. This catecholamine surge par-
ticipates in postnatal cardiac adaptation by increasing blood 
pressure and cardiac inotropic effects; it also is involved in 
metabolic switching by mediating glucagon secretion and 
decreasing insulin secretion as well as induction of thermo-
genesis [86, 92].
Insulin-like growth factor-1 (IGF-1) is an anabolic hor-
mone that is involved in regulation of proliferation, differ-
entiation and postnatal growth of the fetus. This hormone 
is supplied to the fetus from the placenta during early 
gestation, and it increases during the last trimester due to 
secretion from the fetal liver [100]. Indeed, IGF-1 increases 
from 40 µg/L at 18th gestational week to almost 160 µg/L 
at birth [101]. Circulating levels of IGF-1 are regulated by 
growth hormone (GH) and insulin at both transcriptional and 
posttranscriptional levels [101]. These three hormones are 
essential for metabolic homeostasis; indeed, they regulate 
nutrient availability in order to provide adequate substrates 
for growth [80, 102]. Insulin per se promotes fetal growth 
by enhancing the cellular uptake of glucose and potentially 
other energy substrates, like amino acids. Fetal pancreatec-
tomy in sheep results in a significant decrease in glucose 
uptake and oxidation and 30% decrease in fetal growth; 
conversely, high fetal insulin levels (such as from maternal 
diabetes) are associated with increased body weight [78, 
103]. Accordingly, rat cardiomyocytes treated with insulin 
increased plasma membrane expression of the fatty acid 
transporter Cd36 and Glut4, with a subsequent decrease in 
their localization in the microsomal fraction [104]. Growth 
hormone controls fetal development by stimulating hepatic 
release of IGF-1; excess production of GH (acromegalic car-
diomyopathy) or decreased levels of GH (GH deficiency) 
both result in cardiac developmental defect [105]. IGF-1 
stimulates protein synthesis by modulating the PI-3 kinase/
mTOR pathway, and it also regulates free fatty acid utili-
zation in skeletal muscles, potentially via modulation of 
Cd36 [106]. In vitro studies on neonatal rat cardiomyocytes 
demonstrated that IGF-1 treatment increases maturation of 
contractile apparatus as well as induces hypertrophy [107].
Postnatal adaptations are also mediated by air breathing, 
which induces the closure of the ductus arteriosus and the 
foramen ovale, along with marked vasodilation of the pul-
monary vasculature, resulting in a low-pressure pulmonary 
circulation, a higher pressure systemic circulation and near-
100% oxygenation of hemoglobin [108]. Indeed, the oxy-
gen tension in the fetal circulation is only 25–28 mmHg, as 
evaluated in ascending aorta of fetal lamb [109]; this is due 
to the presence of the different shunts resulting in the mixing 
of arterial and venous blood [109].
On a tissue levels, the paracrine signals secreted by fibro-
blasts, endothelial cells and smooth muscle cells also modu-
late cardiomyocyte postnatal maturation [110, 111]. These 
stromal-vascular cells encounter almost 70% of the total cell 
population present in the heart and likely contribute to car-
diac maturation [110], although we know much less about 
these interactions. Notably, fibroblasts from the fetal and 
the neonatal or adult heart secrete different signals [111]. 
Co-culture of embryonic cardiomyocytes and embryonic 
fibroblasts from E12.5 to E13.5 mouse embryos stimulate 
cardiac proliferation due to fibroblast-secreted fibronectin, 
collagen, and heparin-binding EGF-like growth factor. Con-
versely, when these same cardiomyocytes are co-cultured 
with adult fibroblast, the proliferative effect is replaced by 
a hypertrophic response [111]. This hypertrophic signaling 
seems to be mediated by increased expression of interleu-
kin-6 (Il6) in the adult fibroblast (58-fold higher compared 
to the embryonic fibroblast), whereas ECM/β1-integrin 
signaling is required for cardiomyocytes proliferation in 
response to growth factors [111]. Accordingly, fibroblasts 
could be detected at E12.5 (mice) and this is associated with 
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increased ECM synthesis, upregulation of β1 integrin and 
increased cardiomyocytes proliferation [111].
Postnatal cardiac adaptation results in a linear increase of 
cardiac output from 120 mL/min at 15–20 weeks of gesta-
tion to 1700 mL/min at birth, and finally to 5000 mL/min 
in the adult [112]. The surge in the afterload and preload, 
together with increasing levels of circulating vasoactive mol-
ecules, increase the left ventricular systolic pressure, which 
rises from approximately 30 mmHg during gestation, to 
75 mmHg at birth, reaching ~ 90 mmHg at 1 year of age [67, 
69, 86, 113]. This increased workload is accompanied by the 
physiological enlargement of the left ventricular chamber, 
with LV end-diastolic volume increasing from 1.4 mL at 
36 weeks of gestation [114] to 2.6 mL in the early neonatal 
period (5 days after birth) and to 150 mL in the adult human 
[115].
Overall, changes in endocrine factors, oxygen tension, 
hemodynamic forces, and the phenotype of noncardiac 
cells are the key extracellular signals marking the end of the 
fetal stage and driving postnatal cardiomyocyte maturation 
(Fig. 2). In the next section, we discuss the main cellular 
modifications triggered by such signals.
Electrical Activity of Postnatal Cardiomyocytes
Early fetal cardiomyocytes differ substantially from their 
adult counterparts in terms of their electrophysiological 
properties, particularly with regards to automaticity (the 
ability to periodically and spontaneously depolarize until 
an action potential is triggered). As reviewed above, while 
automaticity is restricted to specialized cardiomyocytes in 
the adult heart, all early fetal cardiomyocytes show strong 
automaticity [49, 56].The precise molecular basis of cardiac 
automaticity is still being debated. Two main nonexclusive 
mechanisms have been described: (1) the “voltage clock,” 
constituted by a slow, inward sodium current mediated by 
the hyperpolarization-activated cyclic nucleotide-gated 
channels encoded by the HCN gene family (the so-called 
“funny current,” If); and (2) the “calcium clock,” initiated by 
calcium leaks from the sarcoplasmic reticulum (SR) through 
the ryanodine receptor (RYR2), which lead to activation 
the sodium-calcium exchanger (NCX) and result in a net 
depolarizing current (as three  Na+ are imported for each 
exported  Ca2+). The progressive resting membrane potential 
depolarization resulting from these clocks may be further 
amplified by voltage-dependent T-type calcium channels 
(ICaT, encoded by CACNA1G, CACNA1H, and CACNA1I) 
[116, 117]. Of note, while the role of these ion channels in 
Fig. 2  Cardiomyocyte maturation. Fetal cardiomyocytes (CMs) are 
small and round-shaped, with undeveloped mitochondria and sarcom-
eres. Multiple environmental cues, such as mechanical and electrical 
stimuli, extracellular matrix interactions, and interactions with non-
cardiomyocytes drive gradual maturation of CMs. Through neona-
tal and adult stages, CMs become elongated and display increased 
cytoskeletal organization. Expressions of Connexin-43 and N-cad-
herin increase, and mitochondria develop mature cristae. Adult CMs 




regulating the pacemaking activity of the postnatal heart 
is supported by studies in animal models and by clinical 
evidence [118, 119], whether these same mechanisms medi-
ate automaticity in the early embryonic heart is still largely 
unknown [117, 120].
The expression of HCN4 in the working myocardium 
gradually decreases during development, and this channel 
is virtually absent at human postnatal day 37 (Table 1) [121, 
122]. In ventricular mouse cardiomyocytes, the amount of 
inward current that flows through Hcn4 is ~ 7 pA/pF at day 
E10.5, and decreases by 50% at day E16.5 [123]. In humans, 
HCN4 and T-type calcium channels are still detectable in 
neonatal ventricular cardiomyocytes, which could explain 
their retained automaticity and the heart rate variability in 
the first week after birth [123, 124]. In contrast, in the human 
adult working myocardium, the amount of funny current is 
only ~ 1.9 pA/pF [125]. In agreement with its key function 
in calcium and sodium homeostasis during the cardiac cycle, 
expression of NCX increases linearly during embryogenesis 
and is highest at the fetal stage (19th week of gestation). 
Interestingly, during postnatal and adult stages, the levels 
of NCX mRNA are lower compared to that of fetal stage. 
However, the ratio of protein level to mRNA level is higher 
in the adult, indicating that NCX is subjected to substan-
tial posttranscriptional regulation [116, 126, 127]. In E12.5 
mouse embryos, calcium release from the SR is depend-
ent on the inositol 1,4,5-triphosphate receptor (Itpr3) [128]. 
From mouse E16.5 onward, calcium release is mediated 
by the increasing levels of Ryr2, which mediates localized 
 Ca2+-induced-Ca2+-release in the proximity of T-tubules due 
to its association with the L-type calcium channels [128, 
129]. This more refined regulation of intracellular calcium 
levels leads to increased action potential amplitude and 
duration [130]. The expression of SERCA2a, which pumps 
calcium from the cytosol into the sarcoplasmic reticulum, 
linearly increases during development. Interestingly, levels 
of the SERCA2a mRNA do not substantially change between 
embryonic, fetal, neonatal, and adult stages, but SERCA2a 
protein levels largely increase during cardiac maturation, 
indicating the existence of posttranscriptional regulation also 
for this factor [116, 131].
The expression of ion channels involved in cardiac auto-
maticity is thought to be regulated by regionally expressed 
transcription factors like Nkx2.5, Shox2 and T-box tran-
scription factors [121]. Tbx3 is detectable only in the pace-
maker progenitors cells and in the conduction system, and 
its ectopic expression in the working myocardium of mice 
leads to upregulation of Hcn1, Hcn2, Hcn4, and Cacna1g 
[56, 121]. On the contrary, Nkx2.5 represses the expres-
sion of these pacemaking ion channels, possibly via the 
inhibition of Shox2 [121, 132]. In addition, the presence 
of a conserved binding site for the transcriptional repressor 
NSRF (also known as Rest) in the first intron of Hcn4 could 
also modulate its expression [133]. NSRF is a transcrip-
tional repressor that acts through the recruitment of class 
I and class IIa histone deacetylases (HDACs). It is highly 
expressed in ventricular cardiomyocytes from 20-week-
old mice compared to those from embryos at E13.5 [133]. 
Table 1  Features of developing CMs versus hPSC-CMs
a Unless indicated otherwise, all parameters are reported for human cardiomyocytes
Parameters Fetal  CMsa Neonatal  CMsa hPSC-CMs (< 30 days in culture) Adult-CMsa
Morphology
 Surface area 1216 ± 44.6 µm2 [193] 4395 ± 436 µm2 [194] 1000–1300 µm2 [193] 12,315 ± 2103 µm2 [194]
 Capacitance 20.3 ± 4.6 pF [231] NA 24.6 ± 3.3 pF [231] 100–150 pF [195]
 Length-to-width ratio 5:1 (mouse) [149] 5:1 (mouse) [149] 2:1 [27] 7–9.5:1 [197]
Contractility
 Sarcomere length 1.2 µm (piglet) [89] 1.95 µm (rat) [232] 1.6 µm [209] 2.2 µm [26]
 Force production [201] 0.4 mN/mm2 1.2 mN/mm2 0.1 to 0.5 mN/mm2 10–50 mN/mm2
 Isoform [26]
  Titin N2BA N2BA N2BA N2B
  MHC α α α β
  Troponin ssTnI ssTnI ssTnI cTnI
Electrophysiology
 RMP [202, 203] − 40 mV − 60 mV − 40 mV − 85 mV
 If − 7 pA/pF (mouse) [123] − 3.5 pA/pF (mouse) [123] − 4.1 pA/pF [203] − 1.9 pA/pF [125]
 ICaT [202] − 4 pA/pF (mouse) − 2 pA/pF (mouse) Present Absent
 ICaL [202] − 6 pA/pF (mouse) − 8 pA/pF (mouse) − 6 pA/pF − 9 pA/pF
 IK1 6–8 pA/pF (mouse) [131] 6–8 pA/pF (mouse) [131] Absent [26] 12 pA/pF [233]
Metabolism [26] Glycolysis Glycolysis Glycolysis FA OX
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NSRF is potentially involved also in the regional expression 
of T-type calcium channels (Cacna1g and Cacna1h), whose 
expression decreases over time and becomes undetectable in 
the adult working myocardium [131, 133, 134].
Another hallmark of cardiac maturation is the decrease 
in the resting membrane potential, which for ventricular 
myocytes shifts from − 40 to − 70 mV in the fetal stage 
(E12–E18 in mice) to − 85 mV in the adult [135]. The sta-
bilization of the resting membrane potential at a hyperpolar-
ized level further decreases the automaticity of the working 
myocardium. This process is predominantly controlled the 
inwardly rectifier potassium current IK1, which is mediated 
by the Kir2.1 channel encoded by the KCNJ2 gene. In the 
mouse, expression of Kir 2.1 is first detectable at E17.5, 
begins to increase at P1, and is strongly upregulated only 5 to 
8 weeks after birth (Table 1) [127, 131]. This increase could 
be potentially related to the action of the Notch-responsive 
transcription factor Hey2, which is also involved in cardiac 
morphogenesis and ventricular cardiomyocyte terminal dif-
ferentiation [136, 137].
In summary, the electrical activity of the postnatal heart 
is determined by the regional and temporal regulation of 
transcription factors that are expressed throughout the myo-
cardial wall and gradually become restricted to specialized 
area starting from the 5th week of gestation (E12.5 in mice) 
and through the postnatal period [57].
Structural Organization of Postnatal 
Cardiomyocytes
Cardiomyocytes undergo extensive structural changes during 
the postnatal period. Many of the proteins required for sar-
comere formation and cytoskeletal organization are already 
expressed when the heartbeat begins at E22 (E8 in mice), 
but at lower levels or in different isoforms compared to the 
adult (Fig. 2) [138]. A prominent example is titin, the largest 
human protein, which spans from the Z-disk to the M-line 
and is responsible for both sarcomere assembly and integrity. 
During development titin is expressed in multiple isoforms 
as a result of alternative splicing, a process controlled by the 
cardiac-specific splicing regulator RBM20 [139, 140]. The 
fetal isoform N2BA switches to the less compliant N2B iso-
form soon after birth, resulting in increased passive tension 
at a given sarcomere length [139]. This augments myocardial 
stiffness, thereby compensating for the large increase in the 
end-diastolic volume of the left ventricle, which increases 
up to 100-fold from late gestation stage [114] to the adult 
stages in humans [115], as discussed in the previous section. 
Myosin heavy chain (MHC) isoforms in human also switch 
from α-MHC to β-MHC, leading to slower ATPase activity 
and stronger actin binding, both of which are important for 
stronger contractions at slower heart rates [141]. Conversely, 
in rodents, myosin isoform switches from β to α postnatally, 
which accommodates the 3- to fourfold increase in mouse 
heart rate postnatally [142, 143]. Regulatory troponin I (TnI) 
is initially present as the slow skeletal TnI (ssTnI) isoform, 
and after birth it switches to the cardiac isoform (cTnI) [138, 
144]. This is associated with an increase in myofibrillar sen-
sitivity to  Ca2+, promoting stronger contractions soon after 
birth (Table 1) [145].
Besides mature sarcomeres, efficient excitation–contrac-
tion coupling (E–C coupling) and fast conduction rely on 
two structures that are detectable only in adult cardiomyo-
cytes: the T-tubules and the intercalated disks. T-tubules are 
plasma membrane invaginations along the Z-line regions, 
which carry sarcolemmal ion channels deeply into the cell 
and allow juxtaposition with the sarcoplasmic reticulum 
[26]. Intercalated disks are cardiac-specific cell–cell junc-
tional complexes containing desmosomes, intermediate 
junctions and gap junctions that together allow rapid trans-
mission of contractile forces and electrical signals within 
cardiomyocytes [146]. Primordial T-tubules and intercalated 
disks are already detectable in the human fetus, but fully 
mature structures are not complete until age 7 [147–149]. 
T-tubulation requires the expression of developmentally 
regulated membrane proteins like caveolin-3 [150], whose 
expression strikingly increases after birth [95], as well as 
the expression of bridging integrator-1 [151] and junctophi-
lin-2 [152]. The formation of intercalated disks dictates the 
structural anisotropy of the adult cardiomyocyte as it leads 
to the characteristic rod-shape and polarity. Indeed, the 
strong polarization of Connexin-43 and N-cadherin in adult 
cardiomyocytes determines a length-to-width ratio of 7 to 
9.5. Conversely, the lower abundance and circumferential 
distribution of these structural proteins in neonates results 
in a length-to-width of ~ 5 [66, 149]. Maturation also leads 
to progressive myofibril polarization: in mice their orienta-
tion (evaluated as the angle difference made by the myofibril 
compared to the longitudinal axis) is of 6.14 at E18.5 com-
pared to 5.00 at P4 [149], indicating increased alignment.
Collectively, changes in calcium handling proteins, for-
mation of T-tubules and intercalated disks, improved sar-
comere organization, and changes in myofibril protein iso-
forms largely improve the efficiency of E–C coupling and 
increase the myofilament sensitivity to calcium, leading to 
greatly increased contractility [153]. As a result, the contrac-
tile force of human ventricular myocardium goes from ~ 0.4 
mN/mm2 in the fetus to ~ 1.1 mN/mm2 in the neonate, and 
finally to 10–50 mN/mm2 in the adult [154, 155].
Metabolism of Postnatal Cardiomyocytes
The adult heart is one of the most energy-consuming 
organs of the body, followed by the kidney, the brain, and 
the liver [156]. Indeed, the ATP consumption of a healthy 
adult heart is around 30 μmol/min−1 per gram of tissue 
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at rest [157]. Because of the relative shortage of energy 
reserves (ATP is found at ~ 5 μmol/g of heathy cardiac 
tissue [158]), the heart must continuously produce high 
amounts of energy. In the adult, more than 80% of ATP 
production is the result of fatty acid β-oxidation in the 
mitochondria [158, 159]. In contrast, as introduced in Sec-
tion I, the preferential metabolic pathway in the embryo 
and fetus is glycolysis (contributing to more than 80% of 
all ATP) [77, 80, 160]. After birth, the increasing energy 
demand of the growing body combined with new avail-
ability of carbon substrate (feeding on lipid-rich milk) and 
arterial oxygen rapidly converts metabolism from anaero-
bic glycolysis to fatty acid oxidation [160, 161]. Whereas 
levels of fatty acids are less than 0.1 mM in the fetus, 
they increase immediately after birth to ~ 0.4 mM [80]. 
Moreover, the  PaO2 increases from ~ 28 to ~ 100 mmHg 
in the postnatal stage [108, 109]. Such an increase in oxy-
gen levels is required for efficient fatty acid β-oxidation 
[162], as the oxidation of one gram of palmitate requires 
2.4-fold more oxygen than a gram of glucose (with com-
mensurately greater ATP yield). Fatty acid β-oxidation 
is also favored by the postnatal expression of different 
metabolic enzymes. As the newborn develops, the ATP 
consumption in the heart rises continuously, and this 
energy depletion activates the energy-sensing enzyme, 
AMP-kinase (AMPK), which contributes to the meta-
bolic switch toward fatty acids’ utilization by inhibiting 
acetyl-CoA carboxylase (ACC) [163, 164]. Indeed, ACC 
is highly expressed in the fetal and early postnatal periods 
but decreases dramatically within days after birth [165]. 
ACC produces malonyl-CoA, which in turn inhibits the 
activity of CPT1, a transporter required for lipid traffick-
ing across the mitochondrial membrane. The activity of 
ACC is further inhibited by malonyl-CoA decarboxylase 
(MCD), which, like AMPK, is also more active postna-
tally [164]. Overall, the decreased expression and activity 
of ACC after birth improves CPT1 function, leading to 
increased mitochondrial lipid uptake.
The mitochondria themselves also become more func-
tional postnatally due to both increased biogenesis and 
structural remodeling, which facilitates energy production 
and its transfer to the myofibrils and sarcoplasmic reticu-
lum [166]. Neonatal mitochondria are small, lack fully 
developed cristae, and have a low transmembrane potential 
[135, 166]. The fusion and fission of mitochondria are 
the key processes that underlie mitochondria biogenesis 
and maturation [167], and are controlled by different fac-
tors that are highly dynamic after birth [168–170]. Among 
them, the transcriptional coactivators PGC-1α and PGC-1β 
regulate mitochondrial biogenesis in the postnatal heart. 
In particular, PGC-1 controls genes involved in mito-
chondrial fusion, such as the mitochondrial dynamin-like 
GTPase OPA1 and mitofusin 1 and 2 (MFN1 and MFN2), 
and genes involved in mitochondrial fission like dynamin-
related protein 1 (DRP1) and mitochondrial fission protein 
1 (FIS1) [168, 169]. The considerable amount of high-
energy phosphates produced by the adult mitochondria is 
transferred to the myosin ATPase by the phosphocreatine 
shuttle [171]. This facilitated diffusion system is present 
only in the postnatal stage due to the increased cytoskel-
etal organization, and it is highly efficient compared to the 
simple diffusion mechanisms which dominates the fetal 
stage.
Overall, the increased energy demand of the postnatal 
heart is addressed by the metabolic switch from glycolysis 
to oxidative phosphorylation that, combined with mitochon-
drial development and a more refined energy transfer system, 
leads to a highly efficient coupling between energy produc-
tion in the mitochondrion and utilization at the myofibril.
Cell‑Cycle Regulation in Postnatal Cardiomyocytes
The final stage of cardiac growth, sometimes called terminal 
differentiation, is marked by a transition from hyperplasia 
to hypertrophy. DNA synthesis during murine heart devel-
opment (as evaluated by tritiated thymidine incorporation) 
occurs in two temporally different phases: there is high DNA 
synthesis rates in the embryo, e.g., ~ 33% at E12, which 
drops to almost undetectable levels at birth [172]. In the 
early neonatal stage, a second wave of DNA synthesis occurs 
as the cells become binucleated, with a peak labeling of 10% 
at postnatal day P4–6. After postnatal day 10 (P10), DNA 
synthesis is again almost undetectable [172]. In humans, 
cardiomyocyte cell-cycle withdrawal is considerably slower: 
in the first decade of life, 0.01% of cardiomyocytes were in 
the mitotic phase; this percentage decreased significantly 
during adolescence (10–20 years) and it is barely detect-
able in the hearts of 40 years-old subjects [173–176]. The 
vast majority of both human and rodent cardiomyocytes 
undergo a final round of DNA synthesis without mitosis, 
resulting in polyploid cells [172, 175, 176]. Although the 
evolutionary basis for polyploid cardiomyocytes is unknown, 
it may be that the 20-fold myocyte enlargement that occurs 
during hypertrophic growth requires multiple genomes to 
achieve [177]. Interestingly, polyploidy is achieved in dif-
ferent ways by different species. In humans, cardiomyocytes 
undergo DNA synthesis without nuclear division, resulting 
in ~ 75% of cardiomyocytes having polyploid nuclei [175]. 
In rodents, cardiomyocytes undergo both DNA synthesis and 
nuclear division but do not undergo cytokinesis. This results 
in > 90% of adult rodent cardiomyocytes being binucleated, 
with each nucleus containing a diploid chromosomal content 
[172].
Cell-cycle progression is mediated by complexes of cyc-
lins and cyclin-dependent kinases (CDK) like Cyclin E, 
D, and A, which mediate the progression through G1 to S, 
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and Cyclin A and B, which are responsible for the progres-
sion from M to G2. The expression and activity of such 
complexes is developmentally controlled, and reflects the 
distinct proliferative states of the developing heart [177]. 
The expression of these cell-cycle regulators is controlled 
by transcription factors such as the E2F family and Tbx10, 
which promote expression of cyclins and CDKs, whereas 
BTG2 and MEIS1, which are significantly upregulated in 
cardiomyocytes soon after birth, act as negative regulators 
[177–179]. Other transcription factors like SOX6, GATA4, 
and MEF2C affect cell proliferation by modulating the PI3K/
AKT, WNT/β-catenin, and Hippo-YAP pathways [177, 
180–182].
Amongst all of these regulators, the Hippo-YAP path-
way has emerged as a major player in mediating cell-cycle 
withdrawal in cardiomyocytes [182, 183]. Evidence began 
to accumulate when multiple miRNAs were identified that 
enhance neonatal rat cardiomyocyte reentry in vitro and 
adult heart regeneration in vivo [184]. These subsequently 
were shown to target members of the Hippo pathway for 
degradation [185]. Genetic inhibition of the Hippo pathway 
induces cardiomyocyte hyperplasia in fetal mice, in part 
through unrestrained β-catenin signaling [186]. Genetic 
inhibition of Hippo in the adult heart induces cardiomyo-
cyte cell-cycle re-entry [187], and when inhibited after 
myocardial infarction, this induces cardiac regeneration and 
improvement in cardiac function [188]. Thus, manipulation 
of the Hippo pathway has been the most successful means 
to re-induce division in cardiomyocytes. Conversely, activat-
ing this pathway seems to be an important step in postnatal 
maturity.
Oxygen has been proposed as another key regulator of 
cell-cycle withdrawal in postnatal cardiomyocytes. For 
instance, the elevated regenerative capacity of certain 
amphibians and fish correlates with their relatively hypoxic 
habitat [189, 190]. Conversely, the exposure to a hyperoxic 
environment after birth leads murine cardiomyocytes to exit 
the cell cycle, possibly through increasing concentration of 
reactive oxygen species (ROS) and subsequent oxidative 
DNA damage [190].
In summary, postnatal cues at the cellular, tissue, and 
organ levels drive cardiomyocyte maturation to the adult 
phenotype (Fig. 2). Taken together, this suggest that a simi-
lar multifaced approach will be required to increase the 
maturation of stem cell-derived cardiomyocytes.
The Peter Pan Syndrome of Pluripotent Stem 
Cell‑Derived Cardiomyocytes
Despite substantial process, current approaches to increase 
the maturation of hPSC-CMs in vitro only manage to pro-
duce cardiomyocytes with an intermediate or late fetal 
phenotype (Table 1) [8, 25, 26]. This contrasts markedly 
with results from cell transplantation, when cardiomyocytes 
undergo almost complete structural and molecular matu-
ration in rodent [191, 192], guinea pig [18] or nonhuman 
primate hearts [19, 22]. Thus, there is no intrinsic block 
to maturation in hPSC-CMs. The maturation impediment 
results from the inability of our in vitro systems to mimic 
faithfully their natural environment.
The surface area of hPSC-CMs generated by conventional 
protocols is in the range of 1000–1300 μm2 [193], close 
to that of fetal CMs (1216 ± 45 μm2 [193]). On the other 
hand, the surface area for neonatal CMs and adult CMs is 
4395 ± 436 μm2 and 12,315 ± 2103 μm2, respectively [194]. 
In line with these size differences, the membrane capaci-
tance of hPSC-CMs is 17.5 ± 7.6 pF [26], which is ten times 
lower compared to that of adult CMs (100–150 pF) [26, 
195]. hPSC-CMs are also relatively flat, polygonal to round-
shaped,   and have an irregular morphology: The length-to-
width ratio of these cells ranges from 2 to 4 [196], which 
is substantially different to that of adult CMs (7.7 – 9.5, as 
evaluated in isolated human adult CMs [197]). The contrac-
tile force generated by hPSC-CMs ranges from 0.1 to 4 mN/
mm2 [198–201], depending on the condition in which the 
force was measured, but it still significantly lower than that 
of adult CMs (10–50 mN/mm2 [155, 201]).This difference 
may be explained by reduced myofibril content, myofibril 
disarray and sarcomeric immaturity: ultrastructural analy-
sis revealed that hPSC-CMs have immature sarcomeres in 
which only the Z band is sometimes visible, whereas the 
I-band, A-band, and M-band are absent [27]. Moreover, 
the expression of fetal isoforms of titin (N2BA), troponin 
I (ssTnI), and myosin heavy chain (α-MHC), the absence 
of T-tubules and poor polarization of the intercalated disks, 
combined with the low expression of RYR2 and SERCA2a 
collectively lead to inefficient E–C coupling [26, 28, 202]. 
hPSC-CMs are also characterized by strong automaticity and 
significantly depolarized resting membrane potential (RMP), 
which ranges from − 50 to − 60 mV. This is substantially 
more positive than the adult RMP (− 85 mV), and even 
higher than the neonatal one (− 60 mV to − 70 mV) [202, 
203]. Moreover, the electrical immaturity of hPSC-CMs is 
displayed by strong depolarizing currents (such as If and 
ICaT), combined with low/absent IK1 hyperpolarizing cur-
rent (Table 1).
With regards to hPSC-CM metabolism, mitochondria 
are small, fewer in number, and localized in the perinuclear 
region rather than being intermyofibrillar or subsarcolem-
mal as in the adult heart [204]. Further, the rudimentary 
cristae and the low expression of CPT1 on the mitochondrial 
membrane lead to a reduced uptake of fatty acids [205, 206]. 
Therefore, the preferred metabolic substrates of hPSC-CMs 
are glucose and lactate, which as described earlier are pro-
cessed by glycolysis and inhibit fatty acid β-oxidation [77, 
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205–207]. The cell-cycle dynamics of hPSC-CMs are also 
indicative of immaturity, as the cells have a relatively high 
proliferative capacity [208] and low levels of polyploidy 
[209]. Finally, hPSC-CMs globally resemble fetal CMs 
from a transcriptional and epigenetic level, as confirmed 
by genome-wide assays, including RNA sequencing (RNA-
seq), and the analysis of transcription factor-binding (ChIP-
seq), chromatin accessibility (ATAC-seq), and 3D genome 
architecture (Hi-C) [28, 140, 210].
Strategies for hPSC‑CM Maturation
Over the last decade, multiple approaches have been put 
forward to enhance hPSC-CM maturation, as discussed in 
a number of excellent reviews [26, 196, 211]. While the 
scope of this review is distinct, and thus we do not wish to 
present a complete overview of this extensive field, in this 
short section we summarize the state of the art and highlight 
current limitations.
Long-term culture of hPSC-CMs was the first and sim-
plest approach to improve their maturation. Indeed, full 
physiological maturation of human cardiomyocytes occurs 
between 6 and 10 years of age [147]. This can be partially 
mimicked by culturing hPSC-CMs in vitro for up to one year 
[209, 210, 212, 213]. While this approach does not require 
specialized equipment, it is inefficient, expensive, and labor-
intensive. Moreover, even after 200 days of culture, the phe-
notype of hPSC-CMs is nowhere near complete maturation 
(Table 2). Considering that this method also suffers from 
large batch-to-batch variability and limited yield, it is unsuit-
able for scalable production [196, 211].
Physical stimulation either by mechanical or electrical 
means can speed up hPSC-CM maturation by promoting 
expression of contractile proteins and structural organiza-
tion (Table 2) [214], similarly to what is observed during 
natural development [66, 70]. This has been most success-
ful in engineered heart tissues, where mechanical loading 
can be controlled more readily [198–200, 215]. Tissue engi-
neering aims to closely mimic the environment of develop-
ing cardiomyocytes by embedding them into a 3D matrix 
in the presence of other noncardiac cells. For instance, 
progressive increase in afterload leads to increased twitch 
force, highly organized sarcomeres, and increased expres-
sion of β-MHC [214, 216]. Electrical stimulation alone or 
in combination with mechanical stress also enhances E–C 
coupling in engineered heart tissues by promoting gap junc-
tion formation, sarcomere organization, and SERCA2a and 
RYR2 expression [217, 218]. However, long-term expo-
sure to excessive physical stimulation can induce mark-
ers of pathological hypertrophy and fibrosis [214, 217]. 
When 3D-EHTs are further stimulated by electrical and/
or mechanical means, hPSC-CMs grow to develop adult-
like features such as increased sarcomere length (~ 2.2 µm), 
higher mitochondrial density (up to 30% of the cell volume), 
presence of T-tubules, strong oxidative metabolism, and effi-
cient E–C coupling (Table 2) [199, 200, 214, 215, 219]. Fur-
thermore, despite substantial recent progress in automation 
and scalability [215, 220], generation of 3D-EHTs for high-
throughput analyses and/or regeneration of large portions of 
the myocardium is still very challenging.
Multiple approaches have been identified that enhance 
cardiomyocyte maturation in 2D culture. For example, co-
culturing hPSC-CMs with endothelial cells enhances matu-
rity, in part through upregulation of miRNAs miR-125b-5p, 
miR-199a-5p, miR-221, and miR-222 [221]. Cardiomyo-
cytes respond to substrate cues such as nanotopology, and 
culturing them on surfaces containing sub-micrometer 
grooves enhances alignment of the contractile cytoskeleton 
[222]. This has allowed isolation of single myofibrils from 
hPSC-CMs derived from patients with familial cardiomyo-
pathy [223]. Further maturation of conduction velocities and 
calcium handling occurs when the conductivity of the nano-
grooved substrate is enhanced with graphene oxide [224].
Maturation can also be promoted via stimulation with 
growth factors and/or hormones such IGF [208, 225], gluco-
corticoids [34], and T3 [33, 34, 226]. While these individual 
treatments improve to some degree sarcomere organization, 
electrical coupling, and contractility, hPSC-CMs are still 
largely immature. Overexpression of let-7 family miRNAs, 
which are highly upregulated during long-term hPSC-CM 
maturation in vitro, also leads to a more mature phenotype, 
including stimulating fatty acid metabolism, increased cell 
size, sarcomere length, force of contraction, and respiratory 
capacity [227].
We emphasize that, however, with the possible excep-
tion of electrically paced engineered heart tissues, in all of 
these cases hPSC-CMs are still only comparable to neonatal 
cardiomyocytes. Overall, while these approaches are in prin-
ciple easily scalable and may be effective to improve cardiac 
maturation, the lack of a truly mature phenotype still hinders 
application of hPSC-CMs for certain sensitive applications 
such as pharmacology and toxicology studies.
Conclusion and Future Directions
Late gestational and postnatal cardiac development is char-
acterized by multiple complex pathways that gradually pro-
mote the transition of fetal cardiomyocytes into neonatal and 
finally adult stages. Unfortunately, we still have incomplete 
mechanistic knowledge of this process, particularly with 
regard to late gestational development. Thus, we expect 
that major advances in our ability to mature hPSC-CMs will 
rely on much more extensive studies of the basic biology 
underlying physiological cardiac maturation. Nevertheless, 







































































































































































































































































































































































































































































































































































































































































already known to control cardiac maturation, which have not 
yet been extensively tested in hPSC-CMs.
At least two important aspects must be considered while 
trying to achieve hPSC-CM maturation. First, the required 
level of maturation will heavily depend on the specific 
application. For instance, a truly adult phenotype would be 
highly advantageous for pharmacology, toxicology, and dis-
ease modeling studies. However, this might be unfavorable 
for regenerative medicine applications since adult cardio-
myocytes do not survive transplantation into injured myo-
cardium (while fetal and neonatal cells are more suitable 
[228]). Thus, cardiac maturation can represent a double-
edged sword that must be carefully balanced: we submit that 
a “one size fits all” approach is neither the most efficient nor 
appropriate way to tackle this problem.
The second key issue is one of scalability of mature 
hPSC-CMs production. As discussed, while many efficient 
approaches already exist to increase hPSC-CM maturation, 
most of these cannot currently be applied in a high-through-
put fashion and/or for the generation of the large numbers 
of hiPSC-CMs required for regenerative medicine appli-
cations (which is estimated to require billions of cells per 
patient). Indeed, current “natural engineering” strategies to 
drive hPSC-CM maturation achieve results that are roughly 
proportional to the number of nature’s cues that are being 
replicated in vitro. However, increasing the complexity of 
the culture conditions inversely correlates with scalability, 
costs, and reproducibility. Thus, we propose that methods 
that take not just inspiration from developmental lessons but 
are also able to implement them in novel ways will be highly 
valuable in the future. For instance, the ability to engineer 
cellular phenotypes with high efficiency by means of gene 
editing with CRISPR/Cas9 technology [229, 230] opens 
the opportunity to specifically alter transcriptional gene 
networks and/or specific metabolic pathways, ion channels, 
or sarcomeric proteins.
Overall, we hope that the knowledge gathered in this 
review may catalyze further explorations of the fundamen-
tal link between “natural” and “engineered” development 
to unlock the full potential of hPSC-CMs in the biomedical 
sciences.
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